Clinical Trials Browser

OTHER × disitamab vedotin × 1 year × Clear all

NCT07509424 2026-04-03

Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance

Phase 2 Not yet recruiting

Gastrointestinal

Rectal Neoplasms

NCT07507526 2026-04-02

DTP-HER2

Phase 2 Not yet recruiting

Gastrointestinal

Gastric Adenocarcinoma

NCT07490990 2026-03-24

A Real-World, Single-Arm Study Protocol of Disitamab Vedotin in Combination With Immunotherapy and Multimodal Radiation Therapy for HER2-Positive Advanced Gastric Cancer: After Second-Line Treatment Failure

Not yet recruiting

Gastrointestinal

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

NCT07474064 2026-03-17

Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC

Phase 2 Not yet recruiting

Muscle Invasive Bladder Cancer (MIBC)

NCT07446452 2026-03-03

Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

Phase 2 Recruiting

HER2-low Breast Cancer

NCT07366840 2026-01-26

BRIGHT

Phase 2/3 Not yet recruiting

Breast Neoplasms

NCT05831878 2025-11-18

RC48-ADC in HER2-low Advanced Breast Cancer

Phase NA Recruiting

Advanced Breast Cancer

NCT05851677 2025-09-17

Disitamab Vedotin (RC48-ADC) in Breast Cancer

Breast Neoplasms

NCT07159217 2025-09-08

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Biliary Tract Neoplasms

NCT07142200 2025-08-26

DECIDING

Phase 2 Not yet recruiting

Neoplasms

NCT07065435 2025-07-15

RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

Phase 2 Recruiting

Breast Neoplasms

NCT06540729 2025-07-08

DAB

Phase 2 Recruiting

Ovarian Neoplasms

NCT06957561 2025-05-04

DIVON

Phase 1/2 Not yet recruiting

Urinary Bladder Neoplasms